Cambridge Cognition Holdings
COG · AIM · Health Care · mcap £15m · 28.0p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 06 Oct 26 | COG joins Imperial College-led NHS Study
Cambridge Cognition joins Imperial College-led NHS study bringing earlier |
+0.0% | |
| 23 Sep 26 | Director dealing | Director/PDMR Share Purchases
Cambridge Cognition Holdings plc (AIM: COG), the neuroscience technology company, was informed on 18 September 2026 that, on the same day, Nick Rodgers, Non-Executive Chair of the Company, purchased 19,000 ordinary share |
+1.8% |
| 21 Sep 26 | Partnership with C2N and The Alzheimer's Trust
C2N Diagnostics Expands Global Partnerships in United Kingdom on |
+0.0% | |
| 16 Sep 26 | Results | Half-year Results
Interim Results for the six months to 30 June 2026 |
−1.8% |
| 27 Jul 26 | Trading update | Trading Update
Cambridge, UK, 27 July 2026: Cambridge Cognition Holdings plc (AIM: COG), the neuroscience technology company whose digital cognitive assessments drive scientific discovery, accelerate drug development and improve patien |
+0.0% |
| 23 Jul 26 | Holding | Holding(s) in Company | |
| 22 Jul 26 | Holding | Holding(s) in Company | |
| 15 Jul 26 | Holding | Holding(s) in Company | |
| 10 Jul 26 | Director dealing | Result of GM, TVR & Director/PDMR Dealing
Results of General Meeting, Total Voting Rights and Director/PDMR Dealing |
+0.0% |
| 30 Jun 26 | Fundraise | Result of Retail Offer
Cambridge Cognition (AIM: COG), the neuroscience technology company whose digital cognitive assessments drive scientific discovery, accelerate drug development and improve patient care, announces that the Retail Offer la |
−1.5% |
| 24 Jun 26 | Fundraise | Retail Offer
Cambridge Cognition (AIM: COG), the neuroscience technology company whose digital cognitive assessments drive scientific discovery, accelerate drug development and improve patient care, is pleased to announce a retail of |
−1.4% |
| 24 Jun 26 | Fundraise | Result of Placing & Posting of Circular
Cambridge Cognition (AIM: COG), the neuroscience technology company whose digital cognitive assessments drive scientific discovery, accelerate drug development and improve patient care, is pleased to announce that, furth |
−1.4% |
| 23 Jun 26 | Fundraise | Proposed Equity Fundraising and Retail Offer
THIS ANNOUNCEMENT SHOULD BE READ IN ITS ENTIRETY. |
−1.4% |
| 01 Jun 26 | COG to present at Mello 2026
Cambridge, UK, 1 June 2026: Cambridge Cognition Holdings plc (AIM: COG), the neuroscience technology company whose digital cognitive assessments drive scientific discovery, accelerate drug development and improve patient |
+0.0% | |
| 28 May 26 | Launch of brain health study with Oura
Cambridge Cognition and Oura launch large-scale brain health study integrating cognition with wearable sleep and physiological data |
+8.8% | |
| 21 May 26 | Routine | Result of AGM | |
| 24 Apr 26 | Routine | Posting of Annual Report & Notice of AGM | |
| 13 Apr 26 | Results | Results for the year ended 31 December 2025
Results for the year ended 31 December 2025 |
−1.3% |
| 07 Apr 26 | Routine | Notice of Results | |
| 07 Apr 26 | Appointment of Nominated Adviser and Joint Broker
Cambridge Cognition Holdings plc (AIM: COG), the neuroscience technology company whose digital cognitive assessments drive scientific discovery, accelerate drug development and improve patient care, announces the appoint |
+0.0% | |
| 01 Apr 26 | Routine | Block Listing Return | |
| 11 Mar 26 | Monument Therapeutics MT1988 First Patient Dosed
Cambridge Cognition Investment, Monument Therapeutics, Announces First Patient Dosed in Clinical Trial of MT1988 in Patients at Clinical High Risk for Psychosis |
−2.5% | |
| 16 Feb 26 | Commercialisation Agreement
to scale early cognitive screening with CANTAB Pathway™ in India |
+10.1% | |
| 09 Feb 26 | Change of Joint Broker
Cambridge Cognition Holdings plc (AIM: COG), the neuroscience technology company whose digital cognitive assessments drive scientific discovery, accelerate drug development and improve patient care, announces the appoint |
+0.0% | |
| 19 Jan 26 | Trading update | Trading Update
Trading update for the year ended 31 December 2025 |
+1.8% |
| 05 Nov 25 | Change of Auditor
Cambridge Cognition Holdings plc (AIM:COG), the brain health software group specialising in digital health products that advance brain health research and treatment, announces the appointment of Cooper Parry Group Limite |
+0.0% | |
| 05 Nov 25 | Board Updates
Cambridge Cognition Holdings plc (AIM: COG), the brain health software group specialising in digital health products that advance brain health research and treatment, announces the following changes to the board of direc |
+0.0% |
Company filings. Not investment advice.